The Complete Looksmaxxing Peptide Protocol — 10 Compounds Explained

Introduction: Looks Maxxing as a Research Framework

“Looks maxxing” is the systematic optimization of physical appearance using every available lever simultaneously. In the popular cultural context, it often refers to lifestyle interventions — sleep, training, diet, grooming, skincare. The peptide research dimension extends this systematically into the molecular: what are the specific biochemical pathways that determine physical appearance, and what research compounds have documented activity at those pathways?

What makes looks maxxing a legitimate research question, rather than purely an aesthetic pursuit, is that appearance is a collection of measurable biological outcomes. Facial structure visibility is determined by subcutaneous fat thickness, measurable via ultrasound adipometry. Body composition is quantified by DXA scanning — fat mass percentage, lean mass percentage, regional fat distribution. Skin quality is assessed objectively via optical profilometry (wrinkle depth parameters), cutometry (skin elasticity), and high-frequency ultrasound (dermal thickness). Even cellular aging — the substrate on which all other interventions act — is measurable through epigenetic age clocks (Horvath, Hannum, GrimAge).

The peptide protocol approaches this systematically. Not through individual interventions applied in isolation, but through concurrent multi-pathway research designed to address appearance from every mechanistic angle simultaneously. Each of the five layers targets a distinct, validated biological pathway. No two layers overlap in their primary mechanism. The result is a research architecture that covers the full mechanism space of physical appearance determinants — body composition, tissue repair, dermal aging, anabolic signaling, and cellular senescence — within a single integrated protocol.

Layer 1 — GLP Core: Body Recomposition as the Foundation of Appearance

Body composition is the foundation of appearance. Not in a superficial sense — in a mechanistic one. The visibility of facial bone structure is determined by the thickness of the subcutaneous fat layer overlying it. Malar eminence prominence, mandibular angle definition, orbital rim visibility, temporal hollowing — all of these are functions of regional facial fat distribution, not bone morphology. Similarly, abdominal definition, limb leanness, and overall body proportions are functions of fat mass percentage and distribution pattern.

Retatrutide (GLP-3 R) occupies Layer 1 of this protocol because it represents the most potent single-compound body fat reduction tool in current research literature. The Phase 2 NEJM 2023 data — −28.7% body weight reduction over 48 weeks at the 12mg dose — is a landmark result. For context, the first GLP-1R agonist data (semaglutide, STEP trials) showed approximately 15% weight reduction. Retatrutide nearly doubled this outcome.

The mechanism is tri-receptor agonism: simultaneous activation of GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GcgR (glucagon receptor). GLP-1R activation reduces appetite via central satiety signaling and slows gastric emptying. GIPR activation enhances the incretin effect and amplifies GLP-1R-mediated satiety. GcgR activation — the key differentiator from semaglutide and tirzepatide — increases hepatic glucose production and critically increases energy expenditure through thermogenic mechanisms. It is this GcgR-driven thermogenic axis that explains Retatrutide's superior efficacy: it does not merely reduce intake; it also increases expenditure.

DXA body composition data from the Phase 2 trial showed approximately 80% of total weight lost was fat mass — lean mass was largely preserved. This lean mass preservation is not incidental; it is mechanistically relevant. Maintaining skeletal muscle during aggressive caloric deficit prevents the “deflated” appearance that can accompany purely caloric weight loss without anabolic support. The GH axis layer (Layer 4) provides this anabolic support directly, closing the loop.

The research question for Layer 1: can tri-receptor GLP agonism produce body recomposition outcomes — specifically fat mass reduction with lean mass preservation — that are reliably predictable and anatomically measurable? And does the resulting change in regional fat distribution produce the predicted changes in facial structure visibility and body proportion ratios? These are measurable hypotheses with validated assessment tools.

Layer 2 — Gut & Repair: Systemic Foundation for the GLP Protocol

GLP receptor agonists fundamentally alter GI physiology. Reduced gastric motility (delayed gastric emptying), changed mucosal stimulation patterns, and altered gut hormone secretion all occur with GLP-1R agonist administration. These are not side effects in the trivial sense — they are mechanistic consequences of the same receptor activation that drives appetite reduction. For research protocols using Retatrutide at meaningful doses, maintaining GI mucosal integrity and supporting systemic tissue health throughout the protocol is not optional — it is prerequisite to sustained research validity.

BPC-157 (Body Protection Compound, 15 amino acids) addresses this through multiple parallel mechanisms. The NO (nitric oxide) system: BPC-157 upregulates eNOS (endothelial nitric oxide synthase) and modulates NO production in GI mucosal tissue, supporting the vasoprotective and motility-regulating functions of NO in the gut. VEGFR2 signaling: BPC-157 activates vascular endothelial growth factor receptor 2, driving angiogenesis and mucosal blood supply. EGFR (epidermal growth factor receptor) activation: directly promotes mucosal cell proliferation and repair. Across 40+ published studies in GI models — gastric ulcer, inflammatory bowel, GI fistula, anastomotic healing — BPC-157 shows consistent, robust mucosal protective and regenerative effects.

Beyond GI mucosa, BPC-157's tissue repair activity extends systemically: tendon healing (Achilles, rotator cuff models), ligament repair, bone fracture consolidation, skin wound closure, and even organ protection models (liver, kidney, heart). The systemic tissue repair dimension is directly relevant during periods of significant body composition change: connective tissue, skin, and supporting structures undergo mechanical stress during significant fat mass loss, and maintaining tissue repair capacity throughout this period supports both functional integrity and appearance outcomes.

TB-500(Thymosin Beta-4, the active peptide fragment) complements BPC-157 through orthogonal mechanisms. The LKKTET motif-driven G-actin sequestration is TB-500's primary mechanism: by binding free G-actin (monomeric actin), TB-500 regulates actin polymerization dynamics, enabling more flexible and responsive cell migration during repair. This is mechanistically distinct from BPC-157's receptor-level actions. TB-500 additionally upregulates VEGF production (ligand level), while BPC-157 upregulates VEGFR2 (receptor level) — creating complementary coverage of the angiogenic axis at both the signal and the sensor. NF-κB suppression adds a systemic anti-inflammatory component. The research question for Layer 2: does maintaining GI mucosal integrity and supporting systemic tissue repair during the GLP-3 R protocol produce measurable differences in inflammatory markers, nutrient absorption metrics, and tissue quality outcomes?

Layer 3 — Skin & Glow: The Two Orthogonal Mechanisms of Facial Skin Aging

Skin is the visible surface of physical appearance — the interface between internal biology and external perception. Skin aging research identifies two fundamentally distinct mechanisms that drive the visible changes of chronological skin deterioration. Understanding their orthogonality is critical to understanding why two compounds are required to cover this layer fully.

Mechanism A: Structural aging. The dermis is a dense extracellular matrix (ECM) composed primarily of type I and III collagen fibrils organized by fibroblasts, with elastin providing elastic recoil, and glycosaminoglycans (GAGs, primarily hyaluronic acid) providing hydration and volume. With chronological aging: collagen synthesis rates decline (fibroblast senescence, reduced TGF-β signaling), existing collagen is progressively cross-linked and fragmented by MMP activity, elastin becomes less functional, and GAG content drops. The visible result: skin thinning, loss of firmness, decreased elasticity, surface texture changes, and the deepening of static lines. This is the structural deterioration of the dermal scaffold.

GHK-Cu targets Mechanism A with unmatched mechanistic breadth. Its 4,177-gene transcriptome interaction (Pickart 2010) includes direct upregulation of TGF-β1 (the master regulator of ECM synthesis), collagen I and III genes, elastin, fibronectin, and hyaluronic acid synthesis pathways. Simultaneously, it modulates MMP/TIMP ratios toward net collagen accumulation rather than degradation. The copper chaperone function enhances SOD1 and catalase activity — the antioxidant enzymes that protect the dermal ECM from UV-induced and metabolic ROS damage. The result, confirmed across multiple controlled clinical studies, is measurable increases in dermal collagen density, skin firmness (+49% in 12-week vehicle-controlled research), and reduction in wrinkle depth parameters.

Mechanism B: Neuromuscular aging.Dynamic expression lines — the wrinkles that form at crow's feet, forehead creases, glabellar lines, and perioral regions — are caused by decades of repeated facial muscle contraction. Each contraction is initiated by the neuromuscular junction (NMJ): a motor neuron releases acetylcholine (ACh), which crosses the synaptic cleft and binds nicotinic receptors on the muscle membrane, triggering contraction. The ACh release mechanism requires the SNARE (Soluble NSF Attachment Protein Receptor) complex — specifically SNAP-25, syntaxin, and VAMP — to fuse synaptic vesicles with the presynaptic membrane. With each contraction, a crease is reinforced at the skin surface until it becomes a permanent static line. This mechanism is entirely orthogonal to structural ECM degradation — it is a neuromuscular origin, not a dermal fibroblast origin.

SNAP-8 (Acetyl Glutamyl Heptapeptide-3) addresses Mechanism B through competitive SNARE complex interference. SNAP-8 mimics the N-terminal domain of SNAP-25, partially competing with native SNAP-25 for inclusion in the SNARE complex assembly. A partially destabilized SNARE complex reduces the efficiency of ACh vesicle fusion, reducing the quantity of ACh released per nerve impulse. Less ACh release means reduced contraction depth per facial expression event. Over time, reduced contraction depth reduces the mechanical imprinting of expression lines at the skin surface. In a double-blind vehicle-controlled clinical study, topical SNAP-8 at 10% concentration reduced expression line depth by 16.1% versus vehicle at 28 days.

Because Mechanism A (structural ECM) and Mechanism B (neuromuscular) are completely orthogonal, using both GHK-Cu and SNAP-8 covers the full mechanism space of facial skin aging research. Neither compound redundantly covers the other's mechanism. This is the defining architectural principle of the Skin & Glow layer: two compounds, two entirely separate mechanisms, complete coverage of the domain.

Layer 4 — Lean Mass: Dual Benefits for Body Composition and Skin Quality

Layer 4 is one of the most architecturally important in the protocol because its two compounds — CJC-1295/Ipamorelin and IGF-1 LR3 — serve dual roles that cross layer boundaries. They address both body composition (supporting lean mass preservation during the GLP-3 R caloric restriction protocol) and skin quality (driving dermal fibroblast collagen synthesis via IGF-1R). This cross-layer function reflects the natural interconnectedness of the GH/IGF-1 axis with both metabolic and dermal biology.

The GH axis and somatopause.Growth hormone (GH) secretion is pulsatile, predominantly occurring during deep sleep (slow-wave). With aging — a process called somatopause — these pulses progressively decline in amplitude and frequency, with most adults experiencing significant GH decline from their 30s onward. GH drives hepatic IGF-1 production, and circulating IGF-1 acts systemically on muscle (protein synthesis via IGF-1R → PI3K/AKT → mTOR), adipose tissue (lipolysis), bone (osteoblast stimulation), and dermis (fibroblast collagen synthesis). The somatopause therefore contributes to the age-related pattern of reduced lean mass, increased fat mass, thinner and looser skin, and reduced bone density that collectively define the “aged body composition appearance.”

CJC-1295/Ipamorelin addresses somatopause through complementary mechanisms. CJC-1295 (with DAC — Drug Affinity Complex, albumin-binding) is a GHRH (growth hormone releasing hormone) analogue. GHRH acts at the pituitary to increase GH pulse amplitude. The DAC modification extends half-life from minutes (native GHRH) to approximately 8 days (CJC-1295 DAC), enabling less frequent administration while maintaining sustained GHRH receptor occupancy. Ipamorelin is a selective GHS-R1a (growth hormone secretagogue receptor 1a) agonist — a ghrelin receptor agonist. GHS-R1a activation increases GH pulse frequency rather than amplitude. The combination of increased amplitude (CJC-1295) and increased frequency (Ipamorelin) produces a synergistic GH secretion enhancement that more closely approximates youthful GH secretion patterns than either compound alone.

IGF-1 LR3 provides direct downstream IGF-1R stimulation, bypassing the hypothalamic-pituitary axis entirely. The LR3 variant adds a 13 amino acid N-terminal extension and an Arg→Glu substitution at position 3 that reduces IGF-binding protein (IGFBP) affinity approximately 1,000-fold versus native IGF-1. Since IGFBPs sequester approximately 99% of circulating IGF-1 in the free inactive form, the LR3 modification dramatically increases the fraction of administered compound available for receptor binding. Half-life extends from ~12–15 minutes (native IGF-1) to approximately 20–30 hours (LR3).

The dual appearance benefits of Layer 4: (1) During caloric restriction, GH-driven lipolysis and IGF-1-driven protein synthesis work in concert to direct energy substrate utilization toward fat burning while preserving (and potentially synthesizing) lean muscle mass — directly supporting the body composition goal of Layer 1. (2) Dermal fibroblasts express IGF-1R, and its activation drives synthesis of collagen I, collagen III, elastin, and hyaluronic acid — independently enhancing skin quality through a completely different pathway than GHK-Cu (which works through TGF-β1 upregulation, not IGF-1R). Two independent collagen synthesis pathways operating simultaneously — the PI3K/AKT/mTOR translational pathway (IGF-1 LR3) plus the TGF-β1 transcriptional pathway (GHK-Cu) — is one of the most important synergies in the entire protocol.

Layer 5 — Longevity: The Cellular Substrate for All Other Layers

The longevity layer occupies a unique architectural position: it does not target appearance directly. It targets the cellular capacity to respond to all the other signals in the protocol. If fibroblasts are senescent — as they progressively become with chronological aging — their ability to respond to GHK-Cu's TGF-β1 stimulation or IGF-1 LR3's PI3K/AKT activation is attenuated. Senescent cells are metabolically compromised: reduced mitochondrial function limits ATP availability for protein synthesis; shortened telomeres engage the DNA damage response (DDR), redirecting cellular resources from synthesis to maintenance; reduced NAD+ levels deplete sirtuin activity, impairing mitochondrial biogenesis and DNA repair capacity. The longevity layer addresses these foundational cellular aging mechanisms — restoring the cellular environment in which all other protocol layers operate.

Epithalon (Ala-Glu-Asp-Gly, tetrapeptide) is the most researched compound for telomerase activation in somatic cells. Discovered by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Epithalon upregulates TERT (telomerase reverse transcriptase) expression in somatic cells — the catalytic component of the telomerase enzyme that elongates telomeres. In normal human somatic cells, telomerase is epigenetically silenced after embryonic development. Progressive telomere shortening with each cell division eventually triggers replicative senescence or apoptosis. By partially restoring TERT expression, Epithalon research demonstrates telomere elongation in aged cell cultures and in vivo models. In SHR (spontaneously hypertensive rat) models, Epithalon treatment groups showed a 24% increase in maximum lifespan versus controls. Human lymphocyte studies demonstrated measurable telomere elongation after Epithalon administration. Epithalon also restores melatonin secretion patterns in aged pineal gland tissue — relevant to sleep architecture and circadian regulation, both of which have documented effects on skin repair and GH secretion rhythms.

NAD+ (nicotinamide adenine dinucleotide) is the foundational coenzyme for cellular energy metabolism and a critical substrate for the sirtuin family of protein deacetylases. NAD+ levels decline approximately 50% between age 30 and 60 — driven primarily by the accumulating expression of CD38 (a NAD+ glycohydrolase that irreversibly consumes NAD+) and by the reduced efficiency of the NAD+ biosynthesis pathway. This decline has cascading consequences: sirtuin activity drops (SIRT1-7 require NAD+ as a co-substrate for every deacetylation reaction); PARP-1 (poly-ADP ribose polymerase, the primary DNA repair enzyme) competes with sirtuins for available NAD+; mitochondrial function declines as SIRT3-mediated mitochondrial biogenesis slows. The result is a cell progressively less capable of energy production, DNA repair, and protein synthesis.

In the context of the protocol, NAD+ restoration supports every other layer: it enables fibroblasts to mount the collagen synthesis response prompted by GHK-Cu and IGF-1 LR3; it supports the mitochondrial activity required for GH signaling and IGF-1-mediated anabolic pathways; it enables SIRT1-mediated regulation of the inflammatory response, complementing BPC-157 and TB-500's anti-inflammatory mechanisms. Epithalon and NAD+ together address the two fundamental axes of cellular aging — telomere integrity and metabolic/epigenetic deregulation — providing comprehensive coverage of the cellular aging mechanism space.

Cross-Layer Synergies: How the Five Layers Amplify Each Other

The protocol architecture is not merely additive — specific mechanistic interactions between layers create synergies that exceed what any individual layer could achieve alone. Four key synergistic interactions are worth explicit analysis:

Synergy A — GLP Core + GH Axis (Layers 1 & 4). During caloric restriction (the metabolic state created by GLP-3 R agonism), endogenous GH secretion patterns are altered. Sustained energy deficit can paradoxically increase GH pulse amplitude but reduce IGF-1 levels due to hepatic GH resistance under caloric restriction (a well-characterized phenomenon). Supplementing with CJC-1295/Ipa maintains GH pulsatility, and direct IGF-1 LR3 administration bypasses the hepatic resistance problem entirely by providing pre-formed IGF-1R ligand. The combination ensures the GH/IGF-1 axis is optimized rather than compromised during the negative energy balance phase — directly protecting lean mass and maintaining the dermal IGF-1R signaling that supports skin quality.

Synergy B — GHK-Cu + IGF-1 LR3 (Layer 3 + Layer 4 crossover).Both compounds stimulate collagen synthesis in dermal fibroblasts, but through completely distinct pathways. GHK-Cu works via TGF-β1 upregulation → SMAD2/3 phosphorylation → transcriptional activation of collagen I/III genes. IGF-1 LR3 works via IGF-1R → PI3K → AKT → mTOR → ribosomal protein translation. TGF-β1/SMAD and IGF-1R/mTOR are independent signaling cascades that can operate simultaneously without feedback inhibition of each other. Concurrent activation of both pathways in fibroblasts creates a “both taps open” scenario for collagen production: increased transcription (GHK-Cu) and increased translation capacity (IGF-1 LR3) working in parallel. This cross-layer interaction is unique to the full 5-layer protocol — it cannot emerge from running either layer alone.

Synergy C — BPC-157 + TB-500 (Layer 2 internal).BPC-157 upregulates VEGFR2 (the VEGF receptor responsible for most of VEGF's angiogenic signaling) while TB-500 upregulates VEGF production itself. The combined effect addresses the angiogenic axis at both ends simultaneously: more VEGF ligand available (TB-500) plus increased receptor sensitivity to VEGF (BPC-157). This complementary receptor/ligand pairing produces more robust angiogenic stimulation than either compound alone — relevant both for GI mucosal vascularization during the GLP protocol and for systemic tissue repair processes.

Synergy D — Epithalon + NAD+ (Layer 5 internal).Telomere maintenance (Epithalon) and sirtuin activity restoration (NAD+) represent two of the three primary “hallmarks of aging” (Hallmarks of Aging framework, Lopez-Otin 2013) addressable by research compounds: telomere attrition (Epithalon) and epigenetic alterations plus mitochondrial dysfunction (NAD+/sirtuins). The third — loss of proteostasis — is indirectly addressed by NAD+'s support of autophagy through SIRT1-mediated deacetylation of ATG proteins. The combination therefore covers the cellular aging mechanism space more comprehensively than either compound alone, restoring the cellular capacity that enables all other protocol layers to function at maximum efficacy.

Research Design Considerations: Measuring Looks Maxxing Outcomes

The validity of the looks maxxing research framework depends on objective outcome measurement. Subjective appearance assessments are insufficient for research purposes — they introduce rater bias, lighting variability, and recall confounds. The following measurement toolkit creates an objective, reproducible outcome framework:

Body composition: DXA (dual-energy X-ray absorptiometry) is the gold standard for research-grade body composition assessment. DXA provides total fat mass, lean mass, bone mineral density, and regional fat distribution (trunk vs. limb vs. android vs. gynoid). Repeat DXA at baseline, 12 weeks, 24 weeks, and 48 weeks tracks body composition response to the GLP Core layer with precision.

Facial adipometry: High-frequency ultrasound (15–50 MHz) enables direct measurement of subcutaneous fat pad thickness at defined facial landmarks — buccal fat pad, submental fat, periorbital fat. Changes in these measurements directly quantify facial fat reduction, which correlates with the structural visibility outcomes discussed in Layer 1.

Skin quality:Optical profilometry (e.g., PRIMOS or equivalent) measures wrinkle depth parameters (Ra, Rt, Rv) at standardized facial sites. Cutometry (Cutometer MPA 580) measures skin elasticity coefficients (R2, R7 — net elasticity, biological elasticity). High-frequency ultrasound (20 MHz) measures dermal thickness. These three instruments together provide quantitative measurement of the outcomes targeted by the Skin & Glow layer.

Epigenetic aging:Epigenetic clock assays (Horvath's DNAm Age, GrimAge, PhenoAge) use whole-blood or saliva DNA methylation profiles to generate a biological age estimate independent of chronological age. Research compounds targeting cellular aging (Epithalon, NAD+) should, in theory, produce measurable deceleration or reversal of epigenetic age acceleration. Baseline and repeat testing (6–12 months) can track this.

Facial landmark metrics: Photogrammetric analysis using standardized lighting conditions (controlled flash setup, consistent distance, neutral expression) can quantify inter-zygomatic width, mandibular width, facial width-to-height ratio, and malar projection scores — the geometric parameters of facial attractiveness that vary with fat distribution. These measurements should be made at baseline and at each follow-up interval.

Inflammatory markers:For Layer 2 (Gut & Repair), tracking CRP (C-reactive protein), IL-6, and TNF-α at baseline and follow-up provides quantitative data on the inflammatory milieu during the protocol — testing the hypothesis that BPC-157 + TB-500 maintains lower systemic inflammation during GLP-3 R administration compared to GLP alone.

Administration Timing: Optimizing Each Layer's Pharmacokinetic Profile

Each compound in the protocol has distinct pharmacokinetic characteristics that dictate optimal administration timing. Running all 10 compounds without attention to timing leaves efficacy on the table. The following is a research administration framework organized by timing rationale:

GLP-3 R (Retatrutide):Weekly subcutaneous injection. Research dose escalation — starting low (e.g., 2mg weekly) and escalating over 8–12 weeks to target research dose reduces GI tolerability issues. The weekly interval aligns with the compound's long half-life (~6 days for modified GLP-1R analogues of this class). Fixed day of the week administration for consistency.

BPC-157: Daily or every-other-day subcutaneous or intramuscular injection. For GI mucosal protection during GLP protocols, daily pre-meal oral administration is a research variant — the BPC-157 molecule survives gastric acid due to its stability and exerts local GI mucosal effects. Oral vs. injectable timing consideration: oral dosing for GI protection, injectable for systemic tissue repair.

TB-500: Twice weekly subcutaneous during active repair or maintenance phases. During periods of significant tissue stress (early GLP dose escalation phase when GI side effects are highest), more frequent administration may be relevant. Once acute phase resolves, twice weekly or weekly maintenance is sufficient.

GHK-Cu: Topical, twice daily (morning and evening). Reconstituted and formulated into a serum or cream vehicle. Topical application targets the dermal fibroblasts directly beneath the application site — facial and neck application for facial appearance outcomes. Storage at 4°C to prevent oxidation of the copper chelate.

SNAP-8: Topical, twice daily with GHK-Cu. Expression line sites (periocular, forehead, perioral). The two can be formulated together or applied sequentially in the same skincare routine — no known interaction between GHK-Cu and SNAP-8 in topical co-formulation.

CJC-1295/Ipamorelin: 2–3× weekly, pre-sleep subcutaneous injection. The pre-sleep timing is critical: natural GH pulsatility peaks during slow-wave sleep (SWS), and GHRH/GHS-R agonism prior to SWS onset synchronizes with and amplifies the natural nocturnal GH pulse rather than creating an ectopic out-of-phase stimulus. This entrainment preserves the physiological pulsatile pattern rather than creating chronic elevation.

IGF-1 LR3: Every other day, AM subcutaneous injection. Morning timing aligns with the peak insulin sensitivity period and the metabolic activity window of the day, when IGF-1R downstream signaling (PI3K/AKT/mTOR) is most likely to drive anabolic outcomes rather than metabolic disruption. Every-other-day spacing respects the ~20–30-hour half-life and avoids IGF-1R downregulation that could occur with daily dosing.

Epithalon:Research cycles of 10–20 days on, followed by extended off-periods (months). Khavinson's protocol research used 10-day courses. Continuous daily administration is not supported by the research literature — TERT upregulation is a transient signaling event, not a chronic supplementation scenario. Cyclical administration respects this.

NAD+ (as NMN or NR precursor, or direct IV NAD+): Daily, morning. Consistent daily dosing to maintain elevated NAD+ substrate availability. Oral precursors (NMN, NR) are converted to NAD+ via the Preiss-Handler or Salvage pathways. Direct NAD+ IV administration provides immediate elevation without the conversion step but requires appropriate research infrastructure.

HPLC Purity: The Non-Negotiable Research Requirement

All 10 compounds in the protocol require >98% HPLC purity for research validity. This is not a quality preference — it is a scientific necessity when running multi-compound concurrent research. Each vial of sub-98% compound introduces unknown quantities of synthesis byproducts, unreacted starting materials, and diastereomeric impurities. At the single-compound level, impurities confound dose-response relationships. At the 10-compound level, they create a combinatorial contamination problem: if each of 10 compounds contributes 2–5% impurity content, any observed outcomes cannot be reliably attributed to the target compounds rather than the collective impurity load.

Third-party HPLC test reports are the verification standard: an independent analytical laboratory running reverse-phase HPLC, reporting peak area percentage for the target compound, and providing mass spectrometry confirmation of molecular identity. Both data points are required — purity percentage (HPLC) and identity confirmation (MS). Suppliers who cannot provide both for every lot, on demand, are not appropriate for research-grade protocols.

our research partner, the affiliate partner of this protocol, supplies all 10 stack compounds at >98% HPLC purity with lot-specific third-party test reports available. The full compound list — Retatrutide, BPC-157, TB-500, GHK-Cu, SNAP-8, CJC-1295 DAC, Ipamorelin, IGF-1 LR3, Epithalon, and NAD+ precursor — is available through a single sourcing point, eliminating the supply chain fragmentation that complicates multi-compound protocol research.

Why This Protocol Represents the Current Research Frontier

Each individual layer of the protocol targets a mechanism with substantial published literature support. Layer 1 (GLP-3 R) has Phase 2 clinical data in NEJM. Layer 2 (BPC-157) has 40+ published studies in peer-reviewed GI and tissue repair journals. Layer 3 (GHK-Cu) has Pickart genomic data plus multiple controlled clinical skin studies. Layer 4 (CJC-1295/Ipamorelin, IGF-1 LR3) rests on decades of GH axis endocrinology literature. Layer 5 (Epithalon, NAD+) builds on the validated hallmarks of aging framework and the NAD+ aging literature that has produced multiple Phase 1/2 human studies on NMN and NR precursors.

No two layers overlap mechanistically. GLP core, gut/repair, skin/dermal, GH axis/lean mass, and cellular aging are five distinct biological domains. Each compound within each layer was selected specifically to cover its mechanism space without redundancy against other layers or other compounds within the same layer. This non-overlapping architecture is what distinguishes the protocol from a list of popular compounds — it is a designed system, not a collection.

The full protocol creates a research environment where every major lever of physical appearance optimization is being investigated simultaneously: metabolic recomposition (GLP), structural tissue maintenance (BPC-157/TB-500), dermal aging reversal at two independent mechanisms (GHK-Cu/SNAP-8), anabolic support for lean mass and skin (CJC/Ipa/IGF-1 LR3), and restoration of cellular aging substrate (Epithalon/NAD+). This simultaneous multi-pathway approach — analogous to combination therapy principles in pharmacology — is the research architecture most likely to produce measurable, comprehensive improvements across all appearance-relevant biological domains.

This is the state of the art in research-grade physical optimization science.